Pulmonary Disorders II
Hoeper MM, Benza RL, Corris P, et al. Intensive
care, right ventricular support and lung transplan-
tation in patients with pulmonary hypertension.
Eur
Respir
J.
2019;53(1):1801906.
https://doi.
org/10.1183/13993003.01906-2018
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/
ERS guidelines for the diagnosis and treatment of
pulmonary hypertension. Eur Heart J. 2022;43(38):3618-
3731. https://doi.org/10.1093/eurheartj/ehac237
Klose H, Chin KM, Ewert R, et al. Temporarily switch-
ing from oral to intravenous selexipag in patients with
pulmonary arterial hypertension: safety, tolerability, and
pharmacokinetic results from an open-label, phase III
study. Respir Res. 2021;22(1):34. https://doi.org/10.1186/
s12931-020-01594-8
Kovacs G, Bartolome S, Denton CP, et al. Definition,
classification and diagnosis of pulmonary hyperten-
sion. Eur Respir J. 2024;64(4):2401324. https://doi.
org/10.1183/13993003.01324-2024
Martin AK, Mercier O, Fritz AV, et al. ISHLT consen-
sus statement on the perioperative use of ECLS in lung
transplantation. Part II. Intraoperative considerations. J
Heart Lung Transplant. 2024:S1053-2498(24)01830-8.
https://doi.org/10.1016/j.healun.2024.08.027
McLaughlin VV, Shillington A, Rich S. Survival in
primary pulmonary hypertension: the impact of epo-
prostenol therapy. Circulation. 2002;106(12):1477-1482.
https://doi.org/10.1161/01.cir.0000029100.82385.58
Muzevich KM, Chohan H, Grinnan DC. Management
of pulmonary vasodilator therapy in patients with
pulmonary arterial hypertension during critical ill-
s13054-014-0523-z
Rich S, Brundage BH. High-dose calcium channel-
blocking therapy for primary pulmonary hypertension:
evidence for long-term reduction in pulmonary arte-
rial pressure and regression of right ventricular
hypertrophy. Circulation. 1987;76(1):135-141. https://doi.
org/10.1161/01.cir.76.1.135
Rich S, Kaufmann E, Levy PS. The effect of high doses
of calcium-channel blockers on survival in primary pul-
monary hypertension. N Engl J Med. 1992;327(2):76-81.
https://doi.org/10.1056/nejm199207093270203
Sahay S, Chakinala MM, Kim NH, Preston IR,
Thenappan T, Mclaughlin VV. Contemporary treatment
of pulmonary arterial hypertension: a U.S. perspec-
https://doi.org/10.1164/rccm.202405-0914so
Sitbon O, Humbert M, Nunes H, et al. Long-term intra-
venous epoprostenol infusion in primary pulmonary
hypertension: prognostic factors and survival. J Am Coll
Cardiol. 2002;40(4):780-788. https://doi.org/10.1016/
s0735-1097(02)02012-0
Torbic H, Tonelli AR. Sotatercept for pulmonary arte-
rial hypertension in the inpatient setting. J Cardiovasc
Pharmacol Ther. 2024;29:10742484231225310. https://
doi.org/10.1177/10742484231225310
Vaidy A, O’Corragain O, Vaidya A. Diagnosis and man-
agement of pulmonary hypertension and right ventricular
failure in the cardiovascular intensive care unit. Crit
Care Clin. 2024;40(1):121-135. https://doi.org/10.1016/j.
ccc.2023.05.003
Zamanian RT, Haddad F, Doyle RL, Weinacker AB.
Management strategies for patients with pulmonary
Med. 2007;35(9):2037-2050. https://doi.org/10.1097/01.
ccm.0000280433.74246.9e
Asthma Exacerbation
Althoff MD, Holguin F, Yang F, et al. Noninvasive
ventilation use in critically ill patients with acute
2020;202(11):1520-1530.
https://doi.org/10.1164/
rccm.201910-2021OC
American Thoracic Society. Proceedings of the ATS
workshop on refractory asthma: current understand-
ing, recommendations, and unanswered questions. Am
doi.org/10.1164/ajrccm.162.6.ats9-00
Camargo CA Jr, Spooner CH, Rowe BH. Continuous
versus
intermittent
beta-agonists
in
the
treat-
ment
of
acute
asthma.
Cochrane
Database
Syst
Rev.
2003;2003(4):CD001115.
https://doi.
org/10.1002/14651858.cd001115
D’Amato G, Vitale C, Molino A, et al. Asthma-related
deaths. Multidiscip Respir Med. 2016;11:37. https://doi.
org/10.1186/s40248-016-0073-0
Fanta
CH,
Rossing
TH,
McFadden
ER
Jr.
Glucocorticoids
in
acute
asthma.
A
critical